论文部分内容阅读
为观察人乳头瘤病毒 6b型 (HPV6b )的重组减毒沙门菌载体疫苗粘膜免疫小鼠的免疫效果及探讨研制治疗尖锐湿疣的治疗性粘膜疫苗的机制 ,我们用构建的HPV6b重组减毒沙门菌粘膜免疫BALB/c小鼠 ,检测了阴道冲洗液中特异的SIgA、血清中IgG、T淋巴细胞增殖以及载体疫苗在机体内的稳定性。结果表明 ,粘膜免疫后 ,实验组与对照组相比较 ,阴道冲洗液中抗HPV6bL1的SIgA差异显著 ,实验组血清中抗HPV6bL1IgG水平低 ,T淋巴细胞增殖明显 ,疫苗在小鼠体内持续存在4 0d以上。研究结果提示我们所构建的重组减毒沙门菌粘膜免疫小鼠后 ,阴道粘膜局部能分泌特异的抗人乳头瘤病毒HPV6bSIgA ,也能激发细胞免疫 ,且此疫苗在小鼠体内能稳定存在。
To observe the immune effect of recombinant attenuated Salmonella typhimurium carrier vaccine mucosal immunized mice of human papillomavirus type 6b (HPV6b) and to explore the mechanism of therapeutic mucosal vaccine for the treatment of condyloma acuminatum, we constructed the recombinant attenuated Salmonella typhimurium BALB / c mice were immunized with mucosa, SIgA specific for vaginal washings, IgG and T lymphocyte proliferation in serum and stability of vector vaccine in vivo were tested. The results showed that after mucosal immunization, compared with the control group, the SIgA of anti-HPV6bL1 in the vaginal washings was significantly different. The level of anti-HPV6bL1 IgG in the vaginal washings was low and the proliferation of T lymphocytes was significant. The vaccine persisted in the mice for 40 days the above. The results suggest that we constructed the recombinant attenuated Salmonella mucosa immunized mice, the vaginal mucosa locally secreted specific anti-human papilloma virus HPV6bSIgA, also can stimulate cellular immunity, and the vaccine in mice can be stable.